HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
The fruquintinib and sintilimab combination demonstrated significant PFS improvements in advanced renal…
HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
September 04, 2025 20:00 ET Â | Source: HUTCHMED (China) Limited HONG KONG…
HUTCHMED to Announce 2025 Half-Year Financial Results
July 03, 2025 04:30 ET Â | Source: HUTCHMED (China) Limited HONG KONG…